Zepbound is the only GLP-1 with a sleep apnea indication on its label, and that one line changes both the dose and who pays. The FDA approved it "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity", in combination with a reduced-calorie diet and increased physical activity.1 This guide covers what that approval means, what the trials behind it found, the dose the label sets for sleep apnea, and the four ways people pay for it.
What exactly is approved
Three conditions are in the indication, and all three matter for coverage:
- Obstructive sleep apnea, the kind caused by the airway collapsing during sleep, not central sleep apnea.
- Moderate to severe. In the trials, moderate meant an apnea-hypopnea index (AHI, the number of breathing pauses and shallow-breathing episodes per hour of sleep) of 15 to 30, and severe meant 30 or more, measured by a sleep study.3
- In adults with obesity. The trials enrolled people with a BMI of 30 or higher.3
Everyone in the trials also had diet and activity counselling, and people with type 2 diabetes were excluded.3 If you have a sleep study showing moderate or severe OSA and a BMI of 30 or more, the indication fits; whether the drug is right for you is your prescriber's call.
Why a weight-loss drug treats a breathing problem
The SURMOUNT-OSA authors set out the logic in one line: obstructive sleep apnea "is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor".10 Extra weight around the neck and upper airway makes the airway more likely to collapse during sleep. A drug that reduces body weight can reduce that pressure, which is why the trial measured both breathing events and weight. Zepbound is not a breathing medicine in the sense that a CPAP machine is; it works on one of the causes.
What SURMOUNT-OSA found
The approval rests on SURMOUNT-OSA: two 52-week trials run under one protocol.3 Trial 1 enrolled 234 people "who were unable or unwilling to use Positive Airway Pressure (PAP) therapy", and trial 2 enrolled 235 people who were already on PAP.3 Both compared the highest dose people could tolerate, 10 mg or 15 mg a week, with placebo.4
| Trial 1: no CPAP | Trial 2: on CPAP | |
|---|---|---|
| AHI at the start (events per hour) | 51.5 | 49.5 |
| Change at week 52, Zepbound | -25.3 | -29.3 |
| Change at week 52, placebo | -5.3 | -5.5 |
| Average BMI at the start | 39.1 | 38.7 |
Source: the NEJM abstract of SURMOUNT-OSA.4 Starting from about 50 breathing events an hour, Zepbound cut roughly half of them over a year, against a small change on placebo. The authors' conclusion: tirzepatide "reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes".4
Two honest limits on reading that table. First, these are averages: some people improved far more and some far less. Second, the trials ran a year; they do not say how long the benefit lasts if the drug stops, and the guide to stopping covers what happens to weight when it does.
Who was in the trials
The people tested matter for whether the results apply to you. In trial 1, participants had "a mean age of 48 years (range: 20 to 76 years), 67% were male"; in trial 2, "a mean age of 52 years (range: 26 to 79 years), 72% were male".9 Everyone had obesity and moderate or severe OSA, and nobody had type 2 diabetes.3 Doses were "escalated over a period of up to 20 weeks to maximum tolerated dosage (MTD) of 10 mg or 15 mg".9 So the results describe people who reached one of the two top doses within about five months and stayed on it for the rest of the year.
Does it replace CPAP?
The trials do not answer that, and neither does the label. Trial 2 enrolled people who were on PAP and kept them on it; trial 1 enrolled people who could not or would not use it.3 So the evidence covers Zepbound alongside CPAP and Zepbound for people already not using CPAP. Stopping a CPAP machine is a decision for your sleep physician, not something a drug label or this page can make.
The dose for sleep apnea
The start is the same as for weight loss: "2.5 mg injected subcutaneously once weekly for 4 weeks", then 5 mg, then up in 2.5 mg steps "after at least 4 weeks on the current dose".2 The difference is the target. For sleep apnea, "the recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly",2 where weight loss also allows 5 mg. On the label's fastest schedule, 10 mg arrives at week 13 and 15 mg at week 21. That matters for cost, because the top doses are the most expensive ones at Lilly.
Side effects in the OSA trials "were similar to those reported" in the weight-loss trials,5 which means mostly nausea, diarrhoea, vomiting and constipation during dose increases. The trial authors describe them as "mostly mild to moderate in severity".4 The Zepbound side effects guide has the label's table by dose.
Safety notes specific to the sleep apnea trials
Most of the safety picture matches the weight-loss trials, but the label reports two items from the OSA studies separately. For pancreatitis, the rate "in the pooled clinical studies for OSA (Studies 5 and 6) was 0.84 patients per 100 years for ZEPBOUND and 0 for placebo-treated patients".8 For gallstones, "similar rates of cholelithiasis were reported" in the weight and OSA trials.8 The symptom the label tells patients to watch for is "severe abdominal pain that may radiate to the back, and which may or may not be accompanied by nausea or vomiting".8
Zepbound, Wegovy and Mounjaro for sleep apnea
People often ask whether another GLP-1 would do. On the labels, the answer is no. Wegovy's indications begin "WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity:" and list weight and cardiovascular uses, but its label, read today, does not mention sleep apnea at all.11 Mounjaro contains the same molecule as Zepbound but is sold for type 2 diabetes, and the OSA trials excluded people with diabetes; the Zepbound vs Mounjaro guide explains why the label, not the molecule, decides coverage and price. For an OSA claim to go through insurance, the drug prescribed matters.
A realistic timeline
On the label's fastest schedule, the first 12 weeks are spent at 2.5, 5 and 7.5 mg; 10 mg starts at week 13 and 15 mg at week 21.2 The trial results were measured at week 52.4 So a fair expectation is several months before you are on a sleep apnea dose, and about a year before you can compare yourself with the trial averages. A repeat sleep study is how your doctor would measure the change; how you feel is part of the picture, but the AHI is the number the approval rests on.
Who pays: four routes
1. Medicare Part D, not the Bridge
This is where the sleep apnea indication matters most. Medicare's GLP-1 Bridge, the $50 a month program that began July 1, 2026, lists who is not eligible, and that list includes people who "have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (but your Part D plan might cover your GLP-1s)".6 In plain terms: with sleep apnea you are routed to your own Part D plan, because treating OSA is a medical use, not weight loss. Whether your plan covers it, and with what prior authorization, is the plan's decision. Our Medicare Bridge checker walks through the rules.
2. Commercial insurance
Some plans that exclude weight-loss drugs cover a drug for a medical indication such as OSA, usually with prior authorization and a sleep study. Plans differ, so the only reliable answer is your plan's own policy. The coverage checker quotes what each insurer we track publishes about Zepbound, word for word.
3. Lilly self-pay
Lilly sells Zepbound directly. Its regular price "for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg".7 At the sleep apnea doses, that is $699 a month. Lilly also offers "the $449 purchase offer on your first purchase of the 7.5 mg, 10 mg, 12.5 mg, or 15 mg Zepbound single-patient-use KwikPen", and to keep it "you must complete your refill purchase ... within 45 days".7 Read the terms before counting on it, and note "governmental beneficiaries excluded".7 We quote Lilly's prices as context; we do not link to Lilly.
4. Telehealth programs
Telehealth programs can prescribe brand Zepbound. These are the partner programs we track that sell it, ranked by what you pay each month all in:
One caution worth stating plainly. Compounded tirzepatide is the same molecule, and it is cheaper, but compounded drugs are not FDA-approved and were not what SURMOUNT-OSA tested. The approval and the trial results on this page belong to Zepbound. The compounded tirzepatide guide covers what that difference means.
What to bring to your appointment
- Your sleep study result with the AHI, since moderate or severe OSA is part of the indication.1
- Your current BMI.
- Whether you use CPAP, and how well it works for you.
- Your insurance or Medicare plan name, so prior authorization can start early.
